Targeted Therapies in Cancer - Fourth International Congress. Epidermal growth factor receptor blockade and immune modulation.
Tawbi
Hussein
H
University of Pittsburgh Cancer Institute, Division of Hematology/Oncology, PA 15232, USA. tawbih@upmc.edu
Agarwala
Sanjiv S
SS
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines / Q000627:therapeutic use; D000068818:Cetuximab; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006360:Heat-Shock Proteins / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use; D000077544:Panitumumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; D009838:Oligodeoxyribonucleotides; C483020:ProMune; C484813:vitespin; D000077544:Panitumumab; D066246:ErbB Receptors; D000068818:Cetuximab